Evaluation of antibody targeted controlled release nanoparticle systems

抗体靶向控释纳米颗粒系统的评估

• 批准号: G1001805/1
• 负责人: Christopher Scott
• 金额: $ 5.79万
• 依托单位: Queen's University Belfast
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1001805%2F1
• 关键词: Evaluation; antibody; targeted; controlled; release

The overarching objective of this proposal is the pilot evaluation of a novel antibody-drugdelivery technology, developed by the academic partner (Bioconjug Chem. 2008:19(8):1561-9; Pharm Res. 2008:25(1):135-46), using novel therapeutic antibodies that have beendeveloped by the industrial partner. Pursuance of this objective will provide the following:1. Development of the Research Fellow?s research expertise, management and leadership2. Development of new patent applications around the data produced3. Technical and commercial evaluation of a new therapeutic approach by the partners4. Development of a portfolio of data to facilitate future project grant application funding toagencies such as the MRCThis project builds on the established links between the industrial and academic partners.These groups have successfully collaborated in the past, producing joint IP, publications inquality journals (Clinical Cancer Research, Bioconjugate Chemistry and PlosONE), andultimately creating jobs and wealth in the local economy. A previous collaboration, focussedon the transfer of a protein engineering technology from the School of Pharmacy (through aKTP scheme; awarded A in final report; regional winner 2008), led to the development of anew bovine TB diagnostic kit by the company, which is currently undergoing evaluation in theUK and Ireland.In this current project, the academic partner has developed a novel nanoparticulate drugdelivery system and has already been provided with commercially insensitive antibodies totest as a proof of principle in vitro by the industrial partner. This project will build on thisbase, examining commercially prioritised antibodies (produced using the platformtechnologies underpinning the company) in relevant in vivo primary and metastatic tumourmodelsWe believe that this programme is an ideal mechanism to fund this pilot project, as it not onlyprovides the scope to undertake the project, but allows the Fellow to learn and champion thetechnology, thus developing their own CV, and provides a framework for further fundingopportunities from the MRC such as the DPFS

该提案的总体目的是对学术合作伙伴开发的新型抗体 - 滴定技术的试点评估（BioconjugChem。2008：19（8）：1561-9; PharmRes。2008：25（1）：135-46），使用新型的治疗抗体是由工业合作伙伴养成的新型治疗抗体。追求此目标将提供以下内容：1。研究研究员的研究专业知识，管理和领导力2。开发围绕数据的新专利申请的开发3。合作伙伴对一种新的治疗方法的技术和商业评估4。开发数据组合，以促进未来的项目授予申请资金资金托管，例如MRCTHIS项目，建立在工业和学术合作伙伴之间的既定联系基础上。这些小组过去成功地合作，生产联合IP，出版物询问期刊（临床癌症研究，生物习惯化学和Plosone和Plosone和Plosone），以及在本地创造的经济和财富。 A previous collaboration, focussedon the transfer of a protein engineering technology from the School of Pharmacy (through aKTP scheme; awarded A in final report; regional winner 2008), led to the development of anew bovine TB diagnostic kit by the company, which is currently undergoing evaluation in theUK and Ireland.In this current project, the academic partner has developed a novel nanoparticulate drugdelivery system and has already been provided with commercially insensitive工业合作伙伴在体外的原理证明抗体。该项目将基于本基础，研究在相关的体内主要和转移性肿瘤中相关的商业优先抗体（使用平台技术生产的抗体），该计划是该计划的理想机制，可以为这项飞行员提供资金，因为它不仅可以为其提供范围，而且还可以为他们提供学习范围，还可以为他们提供范围，并为他们提供了theech的范围，并提供了THET的范围。 MRC的进一步资助项目，例如DPFS